Thomas Kosten
Professor Adjunct, PsychiatryCards
About
Research
Publications
2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.
Fava M, Pani L, De Martin S, Cutler A, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, Guidetti C, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study. The Journal Of Clinical Psychiatry 2025, 86 PMID: 39999772, DOI: 10.4088/jcp.24m15438.Peer-Reviewed Original ResearchConceptsDepressive disorderColumbia-Suicide Severity Rating ScaleOpen-label studyDSM-5</i> criteriaFull analysis setMajor depressive disorderMeasures of depressionSeverity Rating ScaleSexual adverse eventsAntidepressant efficacyTreatment-emergent adverse eventsPostbaseline efficacy assessmentAdverse eventsSuicide attemptsUncompetitive antagonistCognitive functionSafety populationEfficacy assessmentRating ScaleEfficacy measuresMDDDouble-blind studyEmergent adverse eventsLong-term treatmentTreatment-related treatment-emergent adverse eventsPlasma microRNAs to Select Optimal Patients for Antibody Production from Anti-Addiction Vaccines
Kosten T, Koirala A, Nielsen D, Domingo C, Thomas Y, Gunaratne P, Coarfa C. Plasma microRNAs to Select Optimal Patients for Antibody Production from Anti-Addiction Vaccines. Vaccines 2025, 13: 181. PMID: 40006728, PMCID: PMC11860428, DOI: 10.3390/vaccines13020181.Peer-Reviewed Original ResearchDE-miRsAnti-drug antibodiesPlasma microRNAsAnti-addiction vaccinesAnti-cocaine vaccinePotential response biomarkersMiR-150Vaccine trial participantsIllicit amphetamineNon-respondersResponse biomarkersMiRsAntibody respondersAnti-addictiveAntibody levelsAntibody productionStudy predictorsVaccineTrial participantsMicroRNAsCocaineAntibodiesLow ABFalse discovery ratePatientsCELECOXIB ADDED TO RISPERIDONE FOR DEPRESSIVE SYMPTOMS IN FIRST-EPISODE AND DRUG NAÏ VE SCHIZOPHRENIA: PHARMACOGENETIC IMPACT OF BDNF GENE POLYMORPHISMS
Wang *, Chen X, Tian Y, Yu Z, Chen D, Xiu M, Kosten T, Zhang X. CELECOXIB ADDED TO RISPERIDONE FOR DEPRESSIVE SYMPTOMS IN FIRST-EPISODE AND DRUG NAÏ VE SCHIZOPHRENIA: PHARMACOGENETIC IMPACT OF BDNF GENE POLYMORPHISMS. The International Journal Of Neuropsychopharmacology 2025, 28: i158-i159. PMCID: PMC11815116, DOI: 10.1093/ijnp/pyae059.274.Peer-Reviewed Original ResearchHamilton Depression Rating ScaleBrain-derived neurotrophic factorPositive and Negative Syndrome ScaleBrain-derived neurotrophic factor serum levelsBrain-derived neurotrophic factor levelsSchizophrenia patientsTreatment of depressionDepressive symptomsPositive symptomsFirst-episodeSCZ patientsHamilton Depression Rating Scale total scoreBrain-derived neurotrophic factor systemComorbid major depressive disorderTreatment response to antidepressantsTotal scoreEarly stages of schizophreniaBrain-derived neurotrophic factor polymorphismsBrain-derived neurotrophic factor genotypePathogenesis of depressive symptomsBrain-derived neurotrophic factor gene polymorphismImprove treatment of depressionBrain-derived neurotrophic factor signalingHealthy controlsAmerican Journal of PsychiatryAnti-Fentanyl Vaccine Alone and in Combination With Buprenorphine Prevents Distribution and Antinociceptive Effects of Fentanyl
Haile C, Duddupudi A, Cuny G, Norton E, Carper B, Kosten T, Kosten T. Anti-Fentanyl Vaccine Alone and in Combination With Buprenorphine Prevents Distribution and Antinociceptive Effects of Fentanyl. Drug And Alcohol Dependence 2025, 267: 112264. DOI: 10.1016/j.drugalcdep.2024.112264.Peer-Reviewed Original ResearchEmulating a randomized clinical trial with real-world data to evaluate the effect of antidepressant use in PTSD patients with high suicide risk
Miranda O, Qi X, Brannock M, Whitworth R, Kosten T, Ryan N, Haas G, Kirisci L, Wang L. Emulating a randomized clinical trial with real-world data to evaluate the effect of antidepressant use in PTSD patients with high suicide risk. Frontiers In Psychiatry 2025, 15: 1526488. PMID: 39935628, PMCID: PMC11811752, DOI: 10.3389/fpsyt.2024.1526488.Peer-Reviewed Original ResearchPost-traumatic stress disorderSuicide-related eventsPost-traumatic stress disorder patientsPost-traumatic stress disorder populationEffects of antidepressant useIncreased risk of suicideInitiation of antidepressantsRisk of suicideStress disorderSuicide riskAntidepressant useAntidepressantsBehavioral changesSuicideLoss to follow-upRandomized clinical trialsMultiple comparisonsTreatment cessationFollow-upClinical trialsIncreased riskElevated riskPatientsCitalopramVenlafaxine
2024
Integrating Drug Target Information in Deep Learning Models to Predict the Risk of Adverse Events in Patients with Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Miranda O, Qi X, Brannock M, Whitworth R, Kosten T, Ryan N, Haas G, Kirisci L, Wang L. Integrating Drug Target Information in Deep Learning Models to Predict the Risk of Adverse Events in Patients with Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder. Biomedicines 2024, 12: 2772. PMID: 39767679, PMCID: PMC11673068, DOI: 10.3390/biomedicines12122772.Peer-Reviewed Original ResearchPost-traumatic stress disorderAlcohol use disorder patientsAlcohol use disorderComorbid post-traumatic stress disorderUse disorderOpioid use disorderStress disorderSuicidal behaviorPotential therapeutic medicationsDeep learning modelsTarget informationDisordersElectronic medical recordsLearning modelsDepressionPotential therapeutic effectsNeighborhood-level social determinants of healthUniversity of Pittsburgh Medical CenterRisk of adverse eventsNeighborhood-level social determinantsSocial determinants of healthAdverse eventsMedicationAdverse outcomesDeterminants of healthTranscranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation for Depression
Zhou D, Li X, Wei S, Yu C, Wang D, Li Y, Li J, Liu J, Li S, Zhuang W, Li Y, Luo R, Liu Z, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Cho R, Kosten T, Zhang X. Transcranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation for Depression. JAMA Network Open 2024, 7: e2444306. PMID: 39535797, PMCID: PMC11561687, DOI: 10.1001/jamanetworkopen.2024.44306.Peer-Reviewed Original ResearchConceptsSham repetitive transcranial magnetic stimulationActive repetitive transcranial magnetic stimulationSham transcranial direct current stimulationRepetitive transcranial magnetic stimulationActive transcranial direct current stimulationTranscranial direct current stimulationTranscranial magnetic stimulationPrimary outcomeIntention-to-treat approachRTMS interventionSham-controlled randomized clinical trialRepetitive transcranial magnetic stimulation sessionsDirect current stimulationMagnetic stimulationSafety of repetitive transcranial magnetic stimulationDepressive disorderMain OutcomesRandomized clinical trialsTotal scoreCurrent stimulationTranscranial direct current stimulation sessionsDorsolateral prefrontal cortexBaseline to week 2Hamilton Depression Rating ScaleRating ScaleDisorders due to Substance Use: General Approaches
Kosten T, Domingo C. Disorders due to Substance Use: General Approaches. 2024, 2527-2542. DOI: 10.1007/978-3-030-51366-5_92.Peer-Reviewed Original ResearchSubstance use disordersDSM-5ICD-11Depressive symptomsSubstance use disorder criteriaBorderline personality disorderSubstance-induced conditionsGoal of abstinenceDrug withdrawal symptomsPersonality disorderDepressive disorderAgonist maintenanceWithdrawal symptomsAcute detoxificationLifetime substanceSUD diagnosisAbused drugsDevelopmental differencesUrine toxicologySubstance useAlcohol usePsychosocial rehabilitationDisordersDrug useSymptomsDexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024, 34: 7-14. PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisordersUse of Cigarettes and E-Cigarettes, Impulsivity, and Anxiety: Influences on Suicidal Ideation Among Youth and Young Adults in Texas
Wilkinson A, Chen B, Swann A, Graham D, Nielsen D, Kosten T, Loukas A, Mantey D, Bataineh B, Harrell M. Use of Cigarettes and E-Cigarettes, Impulsivity, and Anxiety: Influences on Suicidal Ideation Among Youth and Young Adults in Texas. Nicotine & Tobacco Research 2024, 27: 54-60. PMID: 39028574, DOI: 10.1093/ntr/ntae163.Peer-Reviewed Original ResearchE-cigarette useCigarette useE-cigarettesRisk of suicidal ideationHigh riskCigarette/e-cigarette useTexas Adolescent TobaccoAssociated with higher riskYoung adultsUse of cigarettesSuicidal ideationMixed-effects logistic regressionIncreased risk of suicidal ideationIncreased riskHigher risk of suicidal ideationAdolescent tobaccoInfluence of cigaretteLevels of SESLogistic regressionCigaretteCessation programsTwo-weekMultiple social identitiesRiskAppropriate support
News
News
- December 21, 2021
Dr. Tom McMahon Looks Back